Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Biodesix Inc (BDSX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BDSX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -47.99% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 97.81M USD | Price to earnings Ratio - | 1Y Target Price 3.1 |
Price to earnings Ratio - | 1Y Target Price 3.1 | ||
Volume (30-day avg) 440657 | Beta 1.1 | 52 Weeks Range 0.59 - 2.04 | Updated Date 04/1/2025 |
52 Weeks Range 0.59 - 2.04 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -60.19% | Operating Margin (TTM) -32.04% |
Management Effectiveness
Return on Assets (TTM) -21.81% | Return on Equity (TTM) -337.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 126996701 | Price to Sales(TTM) 1.37 |
Enterprise Value 126996701 | Price to Sales(TTM) 1.37 | ||
Enterprise Value to Revenue 1.78 | Enterprise Value to EBITDA -2.72 | Shares Outstanding 145978000 | Shares Floating 66323831 |
Shares Outstanding 145978000 | Shares Floating 66323831 | ||
Percent Insiders 48.45 | Percent Institutions 40.21 |
Analyst Ratings
Rating 4.83 | Target Price 3.1 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Biodesix Inc
Company Overview
History and Background
Biodesix, Inc. was founded in 2005 and is based in Boulder, Colorado. The company focuses on developing and commercializing diagnostic tests for lung diseases, aiming to improve patient outcomes through personalized treatment strategies. Over time, it has expanded its product portfolio and focused on molecular diagnostics.
Core Business Areas
- Lung Diagnostic Testing: This segment focuses on developing and commercializing in vitro diagnostic tests for lung cancer and other lung diseases. The tests provide information to aid in treatment decisions.
- Services and Collaborations: Biodesix offers services and collaborates with pharmaceutical companies and research institutions to develop and validate diagnostic tests and biomarkers.
Leadership and Structure
The leadership team consists of experienced professionals in the diagnostics and biotechnology industries. The company has a functional organizational structure, with departments focused on research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Nodify XL2: A blood-based test that helps physicians assess the risk of malignancy in patients with lung nodules detected on chest imaging. Competitors: Veracyte (VCYT), Exact Sciences (EXAS). Market share information is not readily available.
- LungStrat Dx EGFR: A plasma-based test that identifies EGFR mutations in non-small cell lung cancer patients. Helps physicians to make more informed treatment decisions. Competitors include Qiagen (QGEN) and Roche (RHHBY). Market share information is not readily available.
- Lung Reflex: A strategy that combines multiple tests to provide a comprehensive evaluation of lung nodules. Competitors: Veracyte (VCYT), Exact Sciences (EXAS). Market share information is not readily available.
Market Dynamics
Industry Overview
The molecular diagnostics industry is growing due to advancements in technology, increasing prevalence of diseases, and the demand for personalized medicine. The lung cancer diagnostics segment is particularly competitive.
Positioning
Biodesix aims to be a leading provider of diagnostic solutions for lung diseases. Its competitive advantages include its focus on lung diseases, proprietary technologies, and partnerships with pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for lung cancer diagnostics is estimated to be in the billions of dollars. Biodesix is positioned to capture a significant portion of this market with its comprehensive testing portfolio.
Upturn SWOT Analysis
Strengths
- Proprietary diagnostic technologies
- Focus on lung diseases
- Partnerships with pharmaceutical companies
- Comprehensive product portfolio
Weaknesses
- Limited market share compared to larger competitors
- Reliance on diagnostic test adoption
- Financial losses
Opportunities
- Expanding the product portfolio
- Increasing market penetration
- Collaborating with healthcare providers
- Growing demand for personalized medicine
Threats
- Competition from larger diagnostic companies
- Changes in reimbursement policies
- Regulatory hurdles
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- VCYT
- EXAS
- QGEN
- RHHBY
Competitive Landscape
Biodesix faces stiff competition from larger, more established diagnostic companies. Its advantages include its focus on lung diseases and proprietary technologies. Its disadvantages include its limited market share and financial resources.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been dependent on the market adoption of Biodesix diagnostic products.
Future Projections: Future growth is expected to be driven by increased adoption of its diagnostic tests and expansion into new markets. Analyst estimates can be found on financial news websites.
Recent Initiatives: Recent initiatives include expanding commercial operations, developing new diagnostic tests, and pursuing strategic partnerships.
Summary
Biodesix is a smaller player in the competitive molecular diagnostics industry, focused on lung diseases. Its proprietary technologies and partnerships are strengths, while limited market share and reliance on adoption pose challenges. Future growth hinges on expanding its product portfolio and market penetration amid competition and regulatory hurdles.
Similar Companies
- VCYT
- EXAS
- CTMX
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Financial news websites
- Analyst reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Market share data is based on limited available information and may not be precise. Consult a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biodesix Inc
Exchange NASDAQ | Headquaters Louisville, CO, United States | ||
IPO Launch date 2020-10-28 | President, CEO & Director Mr. Scott Hutton | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 273 | Website https://www.biodesix.com |
Full time employees 273 | Website https://www.biodesix.com | ||
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, together marketed as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development, and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.